TABLE 2.

Cardiovascular and temperature responses to exercise under different hormonal conditions.

	GnRH Antagonist	E2	E2 + T
Tc threshold (°C)
PCOS	37.28 ± 0.27*	37.34 ± 0.39	37.31 ± 0.71
Control	37.70 ± 0.12	37.22 ± 0.19**	37.53 ± 0.19
Slope, ΔSR/ΔTes
PCOS	1.05 ± 0.54	0.72 ± 0.31	1.69 ± 1.34
Control	0.88 ± 0.17	0.60 ± 0.22	0.97 ± 0.43
r2
PCOS	0.84 ± 0.11	0.81 ± 0.15	0.88 ± 0.10
Control	0.81 ± 0.07	0.84 ± 0.11	0.71 ± 0.09
Peak SR (mg·cm–2min–1)
PCOS	1.09 ± 0.55*	0.96 ± 0.42	0.85 ± 0.41*
Control	0.47 ± 0.11	0.78 ± 0.15**,***	0.44 ± 0.10
Peak HR (bpm)
PCOS	148 ± 16	153 ± 13	155 ± 11
Control	150 ± 10	144 ± 12	145 ± 10
Peak MAP
PCOS	97 ± 8	101 ± 5	98 ± 3
Control	97 ± 18	96 ± 13	95 ± 16
Tsk at 27°C before exercise (°C)
PCOS	34.6 ± 0.3	33.7 ± 1.0	33.7 ± 0.9
Control	33.9 ± 1.3	33.7 ± 1.6	33.7 ± 1.0
Tsk at 35°C before exercise (°C)
PCOS	34.9 ± 0.8	34.9 ± 0.3	34.8 ± 0.4
Control	34.3 ± 1.3	34.9 ± 0.2	35.0 ± 0.5

Data are mean ± SD.

Core temperature (T_c) threshold for sweating onset and slopes correspond to those shown in Figures 2 and 3. Peak sweating rate (SR), HR, and mean arterial pressure (MAP) were at 40 min of exercise under all conditions except during GnRH antagonist administration in the PCOS group, when peak HR occurred at 35 min of exercise.

T_es, esophageal temperature; T_sk, mean skin temperature; r², correlation of T_c versus SR slope; GnRH antagonist, gonadotropin-releasing antagonist (ganirelix acetate) administration; E₂, 17β-estradiol administration; T, testosterone.

^*Different from control, P < 0.05.

^**Different from GnRH antagonist within the group, P < 0.05.

^***Different from E₂ + T within the group, P < 0.05.